EULAR 2009

skip to the content

MabThera Rituximab – B Cell Therapy, Lasting Success

EULAR 2009

Here you can download the EULAR 2009 media materials

Press Release

New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis

Backgrounders

download pdf Roche in rheumatoid arthritis backgrounder

download pdf MabThera backgrounder

download pdf Rheumatoid arthritis backgrounder

Key Abstracts

OP-0022, INHIBITION OF JOINT DAMAGE AND IMPROVED CLINICAL OUTCOMES WITH A COMBINATION OF RITUXIMAB (RTX) AND METHOTREXATE (MTX) IN PATIENTS (PTS) WITH EARLY ACTIVE RHEUMATOID ARTHRITIS (RA) WHO ARE NAIVE TO MTX: A RANDOMISED ACTIVE COMPARATOR PLACEBO-CONTROLLED TR

FRI0256, AUTOANTIBODY-POSITIVE RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS) HAVE ENHANCED CLINICAL RESPONSE TO RITUXIMAB (RTX) WHEN COMPARED WITH SERONEGATIVE PATIENTS